title: Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
abstract: High dose chemotherapy and autologous bone marrow transplantation (ABMT) is an effective form of salvage therapy in patients with relapsed or resistant Hodgkin's disease. Patients with large tumour masses at the time of ABMT have a poorer prognosis and we have therefore administered intermediate dose BCNU, etoposide, cytarabine and melphalan (mini-BEAM) prior to high dose therapy with the same agents (BEAM) and ABMT in such patients. In addition we have used the same strategy in patients with bone marrow infiltration at the time of relapse in an attempt to clear the bone marrow for transplant. A total of 23 patients received mini-BEAM and 21 proceeded to BEAM and ABMT. Platelet engraftment was delayed compared to BEAM recipients who had not received mini-BEAM (P = 0.008) but there was only one procedure related death. Responses to BEAM and ABMT were not predicted by the response to mini-BEAM indicating a dose response effect at the upper end of the dose intensity spectrum. At 2 years, the overall survival and progression free survival are 61% and 46% respectively for this group of Hodgkin's patients with extremely poor prognosis.
authors.affiliation: Department of Haematology, University College and Middlesex School of Medicine, London.
authors.forename: R
authors.initials: R
authors.lastname: Chopra
authors.forename: D C
authors.initials: DC
authors.lastname: Linch
authors.forename: A K
authors.initials: AK
authors.lastname: McMillan
authors.forename: S
authors.initials: S
authors.lastname: Blair
authors.forename: K G
authors.initials: KG
authors.lastname: Patterson
authors.forename: D
authors.initials: D
authors.lastname: Moir
authors.forename: J D
authors.initials: JD
authors.lastname: Richards
authors.forename: P
authors.initials: P
authors.lastname: Cervi
authors.forename: S
authors.initials: S
authors.lastname: Kinsey
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine